Duloxetine
- TRADE NAMES: Cymbalta (Lilly); Yentreve (Lilly)
- INDICATIONS: Depression
- CLASS: Antidepressant, Noradrenaline reuptake inhibitor, Serotonin reuptake inhibitor
- HALF-LIFE: 8–17 hours
5HT1 agonists, Alcohol, Amitriptyline, Artemether/Lumefantrine, Aspirin, Atomoxetine, Cimetidine, Ciprofloxacin, Citalopram, Clomipramine, CYP1A2 inducers, CYP2D6 inhibitors and substrates, Darunavir, Droperidol, Enoxacin, Fesoterodine, Fluoxetine, Fluvoxamine, Iobenguane, Levomepromazine, MAO inhibitors, Meperidine, Moclobemide, Naratriptan, Nebivolol, NSAIDs, Paroxetine Hydrochloride, PEG-Interferon, Quinidine, Sibutramine, SSRIs, St John's Wort, Tamoxifen, Teriflunomide, Thioridazine, Tramadol, Tricyclic antidepressants, Tryptophan, Venlafaxine, Viloxazine, Warfarin
PREGNANCY CATEGORY: C
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of duloxetine in the Informa Healthcare journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 01/31/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric